SAN DIEGO, July 16, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS ) securities between April 29, ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Minister Sharanprakash Patil ensures quality education at Haveri Institute of Medical Sciences, addressing issues and overseeing renovations.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $50.46, demonstrating a -3.02% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories.

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...